The trial met its primary outcome of improvement in the distance pulmonary arterial hypertension patients could achieve during a six-minute walk. Compared to a placebo, seven other endpoints were also statistically significant.
About 40,000 people in the U.S. are diagnosed with pulmonary arterial hypertension, which is a progressive, life-threatening disease, Merck said.
Sotatercept was part of the drugmaker’s $11.5 billion acquisition of Acceleron Pharma in November 2021.
Based on the results, Merck Research Laboratories President Dean Li said, “We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
